|
Status |
Public on Jun 01, 2020 |
Title |
AVAglio_GSM2225621 |
Sample type |
RNA |
|
|
Source name |
AVAglio_GSM2225621
|
Organism |
Homo sapiens |
Characteristics |
age: 65 Sex: Female corticosteroids: On surgical status: Partial resection treatment: Bevacizumab phillips subtype: Proneural tcga subtype: Proneural kps: 50-80 mmse: >=27 rpa: Grade IV os (diagnosis): 28.81 os cnsr (event = 1, censor = 0): 0 mgmt status: Missing
|
Treatment protocol |
Not applicable
|
Growth protocol |
Not applicable
|
Extracted molecule |
total RNA |
Extraction protocol |
Not applicable
|
Label |
Nucleotide/fluorophore barcode
|
Label protocol |
Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.
|
|
|
Hybridization protocol |
Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.
|
Scan protocol |
Per NanoString Total RNA Standard Protocol for formalin-fixed, paraffin-embedded (FFPE) samples.
|
Data processing |
Blanks were not available for the AVAglio dataset, as a result background correction was implemented using global negative control probes. Sample-wise normalization was performed by transforming counts to the log2 scale and subtracting the sample-wise mean of housekeeping genes. Water samples (used for the normalisation) using the NanoStringQCPro package on Bioconductor.
|
|
|
Submission date |
May 14, 2020 |
Last update date |
Jun 02, 2020 |
Contact name |
Radia Johnson |
Organization name |
Genentech
|
Street address |
1 DNA Way
|
City |
South San Francisco |
State/province |
CA |
ZIP/Postal code |
94080 |
Country |
United Kingdom |
|
|
Platform ID |
GPL28485 |
Series (2) |
GSE150604 |
Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio] |
GSE150615 |
Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma |
|
Relations |
Reanalysis of |
GSM2225621 |